{
    "title": "Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles",
    "pmcid": "PMC5561238",
    "summary": "The article explores how variations in HLA Class I and II alleles associate with cutaneous hypersensitivity reactions to the HIV-1 drug nevirapine (NVP). By analyzing the peptide binding properties of these HLA molecules, researchers discovered that specific HLA-C alleles, particularly HLA-C*04:01, significantly predispose individuals to cutaneous hypersensitivity across different ethnicities. Additionally, certain HLA-B alleles provide protective benefits against this hypersensitivity. The study advances understanding of the mechanisms behind drug hypersensitivity by revealing the impact of shared peptide binding grooves among varying HLA alleles, suggesting that these interactions may lead to adverse drug reactions.",
    "study_parameters": [
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 151,
            "Study Controls": 413,
            "Characteristics": "Severe cutaneous toxicity (grade 3 or 4) categorized by National Institute of Allergy and Infectious Disease (NIAID) Division of AIDS criteria",
            "Characteristics Type": "study cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.0001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 3.06,
            "Confidence Interval Start": 2.39,
            "Confidence Interval Stop": 6.88,
            "Biogeographical Groups": "Multiple Groups",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 151,
            "Study Controls": 413,
            "Characteristics": "Symbol allele association analysis: HLA-C0401 vs non-carrier",
            "Characteristics Type": "study cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "< 0.0001",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 5.49,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Asian",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 151,
            "Study Controls": 413,
            "Characteristics": "HLA-C*05:01 association in Caucasian subjects vs non-HLA-C*05:01 carriers",
            "Characteristics Type": "study cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.002",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 2.84,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "Caucasian",
            "Variant Annotation ID_norm": null
        },
        {
            "Study Parameters ID": null,
            "Variant Annotation ID": null,
            "Study Type": "case/control",
            "Study Cases": 151,
            "Study Controls": 413,
            "Characteristics": "HLA-C*18:01 association in African patients vs non-HLA-C*18:01 carriers",
            "Characteristics Type": "study cohort",
            "Frequency In Cases": null,
            "Allele Of Frequency In Cases": null,
            "Frequency In Controls": null,
            "Allele Of Frequency In Controls": null,
            "P Value": "= 0.06",
            "Ratio Stat Type": "OR",
            "Ratio Stat": 4.71,
            "Confidence Interval Start": null,
            "Confidence Interval Stop": null,
            "Biogeographical Groups": "African",
            "Variant Annotation ID_norm": null
        }
    ],
    "var_drug_ann": [
        {
            "Variant/Haplotypes": "HLA-C*04:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Carriage of HLA-C*04:01 vs non-carriage: Odds ratio 3.06 (adjusted for ethnicity), P < 0.0001, indicating a significant association with severe hypersensitivity reactions.",
            "Standardized Sentence": "HLA-C*04:01 is associated with increased cutaneous nevirapine hypersensitivity in individuals of multiple ethnicities.",
            "Alleles": "*04:01",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Specialty Population": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": null,
            "Multiple drugs And/or": null,
            "Multiple phenotypes or diseases And/or": null,
            "Citations": [
                "Carriage of HLA-C*04:01 vs non-carriage: Odds ratio 3.06 (adjusted for ethnicity), P < 0.0001;",
                "The HLA alleles most often associated with cutaneous manifestations of NVP HSR are *HLA-C*04*, commonly carried across ethnicities.",
                "Four digit HLA typing was available for 151 cases and 413 controls. In single allele logistic regression analyses *HLA-C*04:01* was the only allele for which a consistent, significant predisposing relationship for cutaneous manifestations of NVP HSR was observed across all ancestral groups."
            ]
        },
        {
            "Variant/Haplotypes": "HLA-C*05:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Inspection of HLA-C*05:01 shows an odds ratio of 2.84, indicating a significant predisposition to nevirapine hypersensitivity in Caucasians (P = 0.002).",
            "Standardized Sentence": "HLA-C*05:01 is associated with increased cutaneous nevirapine hypersensitivity in Caucasian patients.",
            "Alleles": "*05:01",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Specialty Population": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": null,
            "Multiple drugs And/or": null,
            "Multiple phenotypes or diseases And/or": null,
            "Citations": [
                "However, analyses specific to ancestral groups also revealed several other HLA-C allelic associations indicative of HSR predisposition, namely HLA-C*05:01 in Caucasians (versus non-HLA-C*05:01 carriers: OR = 2.84, P = 0.002)",
                "These HSRs are also noted in patients treated with NVP for HIV post-exposure prophylaxis... Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS)...",
                "[The alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04, commonly carried across ethnicities, as well as HLA-B*35 in Asians and Caucasian patients]"
            ]
        },
        {
            "Variant/Haplotypes": "HLA-C*18:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "Phenotype Category": "toxicity",
            "Significance": "not stated",
            "Notes": "HLA-C*18:01 shows an odds ratio of 2.67 in people of African ancestry, which is indicative of increased risk, albeit not statistically significant (P = 0.2).",
            "Standardized Sentence": "HLA-C*18:01 is associated with increased cutaneous nevirapine hypersensitivity in individuals of African ancestry.",
            "Alleles": "*18:01",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Specialty Population": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": null,
            "Multiple drugs And/or": null,
            "Multiple phenotypes or diseases And/or": null,
            "Citations": [
                "*HLA-C*18:01 in patients with African ancestry (versus non-*HLA-C*18:01 carriers: OR = 2.67, *P* = 0.2; vs non-*HLA-C*04:01/*-C*18:01 carriers: OR = 4.71, *P* = 0.06.",
                "validating the association of *HLA-C* alleles with nevirapine hypersensitivity across different populations."
            ]
        },
        {
            "Variant/Haplotypes": "HLA-B*15:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Associated with protection from nevirapine hypersensitivity with an odds ratio showing significant protective qualities. Carriage of this allele shows odds ratio 0.18, P < 0.0001.",
            "Standardized Sentence": "HLA-B*15:01 is associated with decreased cutaneous nevirapine hypersensitivity in individuals.",
            "Alleles": "*15:01",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Specialty Population": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "decreased",
            "PD/PK terms": null,
            "Multiple drugs And/or": null,
            "Multiple phenotypes or diseases And/or": null,
            "Citations": [
                "In contrast, NVP HSR protection is afforded by a cluster of HLA-B alleles defined by a characteristic peptide binding groove B pocket.",
                "The most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001 and OR = 0.20, p = 0.0003 for models with and without adjustment for the primary HLA-C cluster).",
                "It appears that the protective property of this HLA B62 sub-group is driven by the common B pocket structure of the binding groove."
            ]
        },
        {
            "Variant/Haplotypes": "HLA-DRB1*01:01",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "A secondary association showing an odds ratio of 2.00 (P = 0.01) indicating a risk for cutaneous nevirapine hypersensitivity.",
            "Standardized Sentence": "HLA-DRB1*01:01 is associated with increased cutaneous nevirapine hypersensitivity in individuals.",
            "Alleles": "*01:01",
            "Metabolizer types": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "Specialty Population": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "Other:cutaneous nevirapine hypersensitivity",
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "PD/PK terms": null,
            "Multiple drugs And/or": null,
            "Multiple phenotypes or diseases And/or": null,
            "Citations": [
                "The HLA alleles most often associated with cutaneous manifestations of NVP HSR are *HLA-C*04*, commonly carried across ethnicities, as well as *HLA-B*35* in Asians and Caucasian patients.",
                "Having established that *HLA-C* alleles sharing the HLA-C*04:01 F pocket have a primary predisposing impact on the development of cutaneous NVP HSR, we next sought to elucidate the role of secondary HLA class I and class II effects.",
                "Risk *HLA-B* and *HLA-DRB1* alleles are shared across several *HLA-C* allele groups in addition to the *HLA-C*04:01* F pocket risk group and there is little support for any dominant haplotypic effect in cutaneous NVP HSR risk with the exception of *HLA-B*35:05* carried with *HLA-C*04:01* in Asians which display strong linkage disequilibrium."
            ]
        }
    ],
    "var_pheno_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "HLA-C*04:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Associates with cutaneous nevirapine hypersensitivity across ancestral groups.",
            "Sentence": "HLA-C*04:01 is associated with increased severity of cutaneous hypersensitivity reactions when treated with nevirapine in people with HIV.",
            "Alleles": "HLA-C*04:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "cutaneous hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with",
            "Population Phenotypes or diseases": "HIV",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "1",
            "Citations": [
                "HLA-C*04:01 was the only allele for which a consistent, significant predisposing relationship for cutaneous manifestations of NVP HSR was observed across all ancestral groups (Odds ratio (OR) = 3.06 and P = 0.0001 in whole cohort analysis)",
                "The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities",
                "Thus, the observed association with HLA-C*04 across ethnicities is primarily driven by the unique F pocket motif that HLA-C*04:01 shares with HLA-C*05:01 and HLA-C*18:01 which have dominant effects observed in the Hispanic and African subgroups, respectively."
            ]
        },
        {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "HLA-C*05:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Associated with an increased risk for cutaneous hypersensitivity, particularly in Caucasian ancestry.",
            "Sentence": "HLA-C*05:01 is associated with increased risk of cutaneous hypersensitivity reactions when treated with nevirapine in Caucasian populations.",
            "Alleles": "HLA-C*05:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "cutaneous hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in Caucasian populations",
            "Population Phenotypes or diseases": "HIV",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "2",
            "Citations": [
                "analyses specific to ancestral groups also revealed several other HLA-C allelic associations indicative of HSR predisposition, namely HLA-C*05:01 in Caucasians (versus non-HLA-C*05:01 carriers: OR = 2.84, P = 0.002)",
                "Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.",
                "These HSRs are also noted in patients treated with NVP for HIV post-exposure prophylaxis"
            ]
        },
        {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "HLA-B*15:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "While known to offer protection, this allele's protection against cutaneous reactions is diminished in this study.",
            "Sentence": "HLA-B*15:01 is not associated with decreased risk of cutaneous hypersensitivity reactions when treated with nevirapine.",
            "Alleles": "HLA-B*15:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": "decreased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "cutaneous hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with HIV",
            "Population Phenotypes or diseases": "HIV",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "3",
            "Citations": [
                "However, in this dataset the strength of the protection is diminished when the HLA B62 supertype as a whole is considered or if HLA-B*52:01 is excluded.",
                "The observed association with HLA-C*04 across ethnicities is primarily driven by the unique F pocket motif that HLA-C*04:01 shares with HLA-C*05:01 and HLA-C*18:01 which have dominant effects observed in the Hispanic and African subgroups, respectively.",
                "In contrast, NVP HSR protection is afforded by a cluster of HLA-B alleles defined by a characteristic peptide binding groove B pocket."
            ]
        },
        {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "HLA-DRB1*01:01",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Associates with increased risk of cutaneous nevirapine hypersensitivity.",
            "Sentence": "HLA-DRB1*01:01 is associated with increased risk of cutaneous hypersensitivity reactions when treated with nevirapine.",
            "Alleles": "HLA-DRB1*01:01",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Associated with",
            "Direction of effect": "increased",
            "Side effect/efficacy/other": "risk of",
            "Phenotype": "cutaneous hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with HIV",
            "Population Phenotypes or diseases": "HIV",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "4",
            "Citations": [
                "Adverse drug reactions are associated with considerable global morbidity and mortality and pose a substantial challenge in drug development and implementation.",
                "Nevirapine (NVP) hypersensitivity encompasses different clinical phenotypes with cutaneous, hepatic or systemic symptoms.",
                "The allelic specificity of the HLA peptide binding groove in the pathogenesis of T cell mediated drug hypersensitivity is exemplified by the well characterized abacavir hypersensitivity syndrome which occurs both in vivo and in vitro only in association with HLA-B57:01, and not with related B17 serotype alleles such as HLA-B57:02/3 and HLA-B58:01."
            ]
        },
        {
            "Variant Annotation ID": 5,
            "Variant/Haplotypes": "HLA-DRB1*04:04",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "no",
            "Notes": "Did not associate significantly with cutaneous hypersensitivity when compared to controls.",
            "Sentence": "HLA-DRB1*04:04 is not associated with risk of cutaneous hypersensitivity reactions when treated with nevirapine.",
            "Alleles": "HLA-DRB1*04:04",
            "Specialty Population": null,
            "Metabolizer types": null,
            "isPlural": "Is",
            "Is/Is Not associated": "Not associated with",
            "Direction of effect": null,
            "Side effect/efficacy/other": null,
            "Phenotype": "cutaneous hypersensitivity",
            "Multiple phenotypes And/or": null,
            "When treated with/exposed to/when assayed with": "when treated with",
            "Multiple drugs And/or": null,
            "Population types": "in people with HIV",
            "Population Phenotypes or diseases": "HIV",
            "Multiple phenotypes or diseases And/or": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": "28819312",
            "Variant Annotation ID_norm": "5",
            "Citations": [
                "The identified risk alleles for cutaneous NVP HSR share the sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 over residues forming the P4 pocket... In contrast, the predominantly Caucasian alleles HLA-DRB1*04:01 and -DRB1*04:15 differed from the risk group only at position Î²71 within the P4 pocket, and yet appeared to be protective in this ancestral group (2 cases, 26 controls, p = 0.01).",
                "Cutaneous reactions range in severity from mild rash through to severe diseases with high morbidity and mortality such as Stevens Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS).... The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.",
                "Here, we demonstrate that the observed association with HLA-C*04* across ethnicities is primarily driven by the unique F pocket motif that HLA-C*04:01 shares with HLA-C*05:01 and HLA-C*18:01 which have dominant effects observed in the Hispanic and African subgroups, respectively."
            ]
        }
    ],
    "var_fa_ann": [
        {
            "Variant Annotation ID": 1,
            "Variant/Haplotypes": "HLA-C*04:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine (NVP)",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Consistent significant predisposing relationship observed across ancestral groups (Odds ratio = 3.06, P = 0.0001) for cutaneous NVP hypersensitivity.",
            "Sentence": "HLA-C*04:01 is associated with increased risk of cutaneous nevirapine hypersensitivity as compared to non-carriers.",
            "Alleles": "HLA-C*04:01, HLA-C*05:01, HLA-C*18:01",
            "Specialty Population": null,
            "Assay type": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "*HLA-C*04:01* was the only allele for which a consistent, significant predisposing relationship for cutaneous manifestations of NVP HSR was observed across all ancestral groups (Odds ratio (OR) = 3.06 and *P* = 0.0001 in whole cohort analysis)",
                "The HLA alleles most often associated with cutaneous manifestations of NVP HSR are *HLA-C*04*, commonly carried across ethnicities, as well as *HLA-B*35* in Asians and Caucasian patients.",
                "Carriage of HLA-C*04:01 vs non-carriage: Odds ratio 3.06 (adjusted for ethnicity), P < 0.0001;"
            ]
        },
        {
            "Variant Annotation ID": 2,
            "Variant/Haplotypes": "HLA-B*15:01",
            "Gene": "HLA-B",
            "Drug(s)": "nevirapine (NVP)",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Protective association against cutaneous NVP hypersensitivity, observed with odds ratio = 0.18 and p = 0.0001.",
            "Sentence": "HLA-B*15:01 is associated with decreased risk of cutaneous nevirapine hypersensitivity as compared to non-carriers.",
            "Alleles": "HLA-B*15:01",
            "Specialty Population": null,
            "Assay type": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "the most prominent secondary effect is protection associated with the HLA-B B pocket, which is independent of HLA-C risk (OR = 0.18, p = 0.0001)",
                "this study has considered how peptide binding chemistry of the HLA antigen binding groove impacts cutaneous NVP HSR and has identified the unique F pocket conformation that defines a primary risk cluster of HLA-C alleles",
                "the protective property of this HLA B62 sub-group is driven by the common B pocket structure of the binding groove"
            ]
        },
        {
            "Variant Annotation ID": 3,
            "Variant/Haplotypes": "HLA-DRB1*01:01",
            "Gene": "HLA-DRB1",
            "Drug(s)": "nevirapine (NVP)",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Secondary association with risk of cutaneous NVP hypersensitivity observed in certain ancestral groups.",
            "Sentence": "HLA-DRB1*01:01 is associated with increased risk of cutaneous nevirapine hypersensitivity as compared to non-carriers.",
            "Alleles": "HLA-DRB1*01:01",
            "Specialty Population": null,
            "Assay type": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "In single allele logistic regression analyses HLA-C*04:01 was the only allele for which a consistent, significant predisposing relationship for cutaneous manifestations of NVP HSR was observed across all ancestral groups (Odds ratio (OR) = 3.06 and P = 0.0001 in whole cohort analysis)",
                "The identified risk alleles for cutaneous NVP HSR share the sequence (Phe/His)13-Gln70-Arg71-Ala74-Tyr78 over residues forming the P4 pocket",
                "Risk HLA-DRB1 alleles HLA-DRB1*01:(01/02/03), -DRB1*04:(04/05/08/10) | 2.00 [1.23-3.24] | 1.34 [0.68-2.64] | 3.23 [1.40-7.43] | 4.77 [0.95-24.04]"
            ]
        },
        {
            "Variant Annotation ID": 4,
            "Variant/Haplotypes": "HLA-C*05:01, HLA-C*18:01",
            "Gene": "HLA-C",
            "Drug(s)": "nevirapine (NVP)",
            "PMID": 28819312,
            "Phenotype Category": "toxicity",
            "Significance": "yes",
            "Notes": "Other HLA-C alleles indicative of hypersensitivity predisposition identified with odds ratios suggestive of significant association in certain ethnic groups.",
            "Sentence": "HLA-C*05:01 and HLA-C*18:01 are associated with increased risk of cutaneous nevirapine hypersensitivity as compared to non-carriers.",
            "Alleles": "HLA-C*05:01, HLA-C*18:01",
            "Specialty Population": null,
            "Assay type": null,
            "Cell type": null,
            "Comparison Allele(s) or Genotype(s)": null,
            "Comparison Metabolizer types": null,
            "PMID_norm": null,
            "Variant Annotation ID_norm": null,
            "Citations": [
                "However, analyses specific to ancestral groups also revealed several other HLA-C allelic associations indicative of HSR predisposition, namely HLA-C*05:01 in Caucasians (versus non-HLA-C*05:01 carriers: OR = 2.84, P = 0.002) and HLA-C*18:01 in patients with African ancestry (versus non-HLA-C*18:01 carriers: OR = 2.67, P = 0.2; vs non-HLA-C*04:01/*-C*18:01 carriers: OR = 4.71, P = 0.06).",
                "The HLA alleles most often associated with cutaneous manifestations of NVP HSR are HLA-C*04*, commonly carried across ethnicities, as well as HLA-B*35* in Asians and Caucasian patients.",
                "We thereby provide an explanation for multiple HLA associations with cutaneous NVP HSR and advance insight into its pathogenic mechanisms."
            ]
        }
    ]
}